S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer.

Naruto Taira, Kenjiro Aogi, Shozo Ohsumi, Shigemitsu Takashima, Rieko Nishimura, Hiroyoshi Doihara, Toshiaki Saeki

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We present a patient with pulmonary metastasis from breast cancer who received S-1 (TS-1) and maintained complete response for approximately 10 years after recurrence. A 51-year-old woman underwent modified radical mastectomy for left breast cancer in November 1991. Her cancer was postoperatively classified as pT2 pN0 M0 Stage IIA. As postoperative adjunctive treatment, tamoxifen and hexylcarbamoyl 1-5-FU (HCFU) were given. During the administration period (30 months after surgery), a solitary pulmonary metastasis occurred. Three months after the start of S-1 (100 mg/body/day), the tumor disappeared on images. Thereafter she took S-1 orally for approximately 10 years, and the pulmonary metastatic focus maintained complete response. In addition, no recurrent focus was observed. The adverse events observed during S-1 treatment were nausea, low-grade neutropenia and pigmentation of fingers. All were mild, and S-1 could be continued. Our case illustrates two important characteristics of S-1. First, S-1 was effective even though this patient had a lung metastasis during adjuvant treatment with HCFU. S-1 is a combined formulation containing 5-chloro-2, 4-dihydroxypyrimidine (CDHP; gimestat), which inhibits an enzyme that metabolites 5-FU, dihydropyrimidine dehydrogenase (DPD). Therefore, high 5-FU concentrations are maintained with S-1, and S-1 may be effective in the patients who do not respond to other fluoropyrimidine agents. Second, since S-1 toxicity was mild, long-term treatment for approximately 10 years was possible. Since S-1 contains potassium oxonate (OXO; otastat), gastrointestinal toxicities, the main adverse events of 5-FU agents, could be reduced. The purpose of treatments for metastatic breast cancer is to maintain favorable quality of life (QOL), as well as to improve survival. S-1 could be a valuable agent for breast cancer treatments, since it showed clinical efficacy and mild toxicity, and can be given orally.

Original languageEnglish
Pages (from-to)220-224
Number of pages5
JournalBreast Cancer
Volume13
Issue number2
DOIs
Publication statusPublished - 2006
Externally publishedYes

Fingerprint

Fluorouracil
Breast Neoplasms
Lung
Neoplasm Metastasis
Therapeutics
Dihydrouracil Dehydrogenase (NADP)
Modified Radical Mastectomy
Pigmentation
Tamoxifen
Neutropenia
Nausea
Fingers
titanium silicide
Neoplasms
Quality of Life
Recurrence
Survival
Enzymes

Cite this

S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer. / Taira, Naruto; Aogi, Kenjiro; Ohsumi, Shozo; Takashima, Shigemitsu; Nishimura, Rieko; Doihara, Hiroyoshi; Saeki, Toshiaki.

In: Breast Cancer, Vol. 13, No. 2, 2006, p. 220-224.

Research output: Contribution to journalArticle

Taira, Naruto ; Aogi, Kenjiro ; Ohsumi, Shozo ; Takashima, Shigemitsu ; Nishimura, Rieko ; Doihara, Hiroyoshi ; Saeki, Toshiaki. / S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer. In: Breast Cancer. 2006 ; Vol. 13, No. 2. pp. 220-224.
@article{b126815957194719af6546fff48a7212,
title = "S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer.",
abstract = "We present a patient with pulmonary metastasis from breast cancer who received S-1 (TS-1) and maintained complete response for approximately 10 years after recurrence. A 51-year-old woman underwent modified radical mastectomy for left breast cancer in November 1991. Her cancer was postoperatively classified as pT2 pN0 M0 Stage IIA. As postoperative adjunctive treatment, tamoxifen and hexylcarbamoyl 1-5-FU (HCFU) were given. During the administration period (30 months after surgery), a solitary pulmonary metastasis occurred. Three months after the start of S-1 (100 mg/body/day), the tumor disappeared on images. Thereafter she took S-1 orally for approximately 10 years, and the pulmonary metastatic focus maintained complete response. In addition, no recurrent focus was observed. The adverse events observed during S-1 treatment were nausea, low-grade neutropenia and pigmentation of fingers. All were mild, and S-1 could be continued. Our case illustrates two important characteristics of S-1. First, S-1 was effective even though this patient had a lung metastasis during adjuvant treatment with HCFU. S-1 is a combined formulation containing 5-chloro-2, 4-dihydroxypyrimidine (CDHP; gimestat), which inhibits an enzyme that metabolites 5-FU, dihydropyrimidine dehydrogenase (DPD). Therefore, high 5-FU concentrations are maintained with S-1, and S-1 may be effective in the patients who do not respond to other fluoropyrimidine agents. Second, since S-1 toxicity was mild, long-term treatment for approximately 10 years was possible. Since S-1 contains potassium oxonate (OXO; otastat), gastrointestinal toxicities, the main adverse events of 5-FU agents, could be reduced. The purpose of treatments for metastatic breast cancer is to maintain favorable quality of life (QOL), as well as to improve survival. S-1 could be a valuable agent for breast cancer treatments, since it showed clinical efficacy and mild toxicity, and can be given orally.",
author = "Naruto Taira and Kenjiro Aogi and Shozo Ohsumi and Shigemitsu Takashima and Rieko Nishimura and Hiroyoshi Doihara and Toshiaki Saeki",
year = "2006",
doi = "10.2325/jbcs.13.220",
language = "English",
volume = "13",
pages = "220--224",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer.

AU - Taira, Naruto

AU - Aogi, Kenjiro

AU - Ohsumi, Shozo

AU - Takashima, Shigemitsu

AU - Nishimura, Rieko

AU - Doihara, Hiroyoshi

AU - Saeki, Toshiaki

PY - 2006

Y1 - 2006

N2 - We present a patient with pulmonary metastasis from breast cancer who received S-1 (TS-1) and maintained complete response for approximately 10 years after recurrence. A 51-year-old woman underwent modified radical mastectomy for left breast cancer in November 1991. Her cancer was postoperatively classified as pT2 pN0 M0 Stage IIA. As postoperative adjunctive treatment, tamoxifen and hexylcarbamoyl 1-5-FU (HCFU) were given. During the administration period (30 months after surgery), a solitary pulmonary metastasis occurred. Three months after the start of S-1 (100 mg/body/day), the tumor disappeared on images. Thereafter she took S-1 orally for approximately 10 years, and the pulmonary metastatic focus maintained complete response. In addition, no recurrent focus was observed. The adverse events observed during S-1 treatment were nausea, low-grade neutropenia and pigmentation of fingers. All were mild, and S-1 could be continued. Our case illustrates two important characteristics of S-1. First, S-1 was effective even though this patient had a lung metastasis during adjuvant treatment with HCFU. S-1 is a combined formulation containing 5-chloro-2, 4-dihydroxypyrimidine (CDHP; gimestat), which inhibits an enzyme that metabolites 5-FU, dihydropyrimidine dehydrogenase (DPD). Therefore, high 5-FU concentrations are maintained with S-1, and S-1 may be effective in the patients who do not respond to other fluoropyrimidine agents. Second, since S-1 toxicity was mild, long-term treatment for approximately 10 years was possible. Since S-1 contains potassium oxonate (OXO; otastat), gastrointestinal toxicities, the main adverse events of 5-FU agents, could be reduced. The purpose of treatments for metastatic breast cancer is to maintain favorable quality of life (QOL), as well as to improve survival. S-1 could be a valuable agent for breast cancer treatments, since it showed clinical efficacy and mild toxicity, and can be given orally.

AB - We present a patient with pulmonary metastasis from breast cancer who received S-1 (TS-1) and maintained complete response for approximately 10 years after recurrence. A 51-year-old woman underwent modified radical mastectomy for left breast cancer in November 1991. Her cancer was postoperatively classified as pT2 pN0 M0 Stage IIA. As postoperative adjunctive treatment, tamoxifen and hexylcarbamoyl 1-5-FU (HCFU) were given. During the administration period (30 months after surgery), a solitary pulmonary metastasis occurred. Three months after the start of S-1 (100 mg/body/day), the tumor disappeared on images. Thereafter she took S-1 orally for approximately 10 years, and the pulmonary metastatic focus maintained complete response. In addition, no recurrent focus was observed. The adverse events observed during S-1 treatment were nausea, low-grade neutropenia and pigmentation of fingers. All were mild, and S-1 could be continued. Our case illustrates two important characteristics of S-1. First, S-1 was effective even though this patient had a lung metastasis during adjuvant treatment with HCFU. S-1 is a combined formulation containing 5-chloro-2, 4-dihydroxypyrimidine (CDHP; gimestat), which inhibits an enzyme that metabolites 5-FU, dihydropyrimidine dehydrogenase (DPD). Therefore, high 5-FU concentrations are maintained with S-1, and S-1 may be effective in the patients who do not respond to other fluoropyrimidine agents. Second, since S-1 toxicity was mild, long-term treatment for approximately 10 years was possible. Since S-1 contains potassium oxonate (OXO; otastat), gastrointestinal toxicities, the main adverse events of 5-FU agents, could be reduced. The purpose of treatments for metastatic breast cancer is to maintain favorable quality of life (QOL), as well as to improve survival. S-1 could be a valuable agent for breast cancer treatments, since it showed clinical efficacy and mild toxicity, and can be given orally.

UR - http://www.scopus.com/inward/record.url?scp=33746857783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746857783&partnerID=8YFLogxK

U2 - 10.2325/jbcs.13.220

DO - 10.2325/jbcs.13.220

M3 - Article

C2 - 16755122

AN - SCOPUS:33746857783

VL - 13

SP - 220

EP - 224

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 2

ER -